Report: Drug price spikes threaten patient health, economic stability

December 26, 2016 by Kevin Mccoy, Usa Today

Staggering hikes as high as 5000% in prices of some prescription drugs threaten the health of Americans who can't afford vital medicines as well as the broader economic stability of households across the U.S., a new congressional report warned Wednesday.

The findings by the Senate Special on Aging summarize the panel's 2016 investigation of records from four pharmaceutical companies and public hearings that focused on sudden price spikes in decades-old medications and the pricing decisions imposed by industry entrepreneur Martin Shkreli and others healthcare industry executives.

Turing Pharmaceuticals and Retrophin (RTRX), two firms once headed by Shkreli, embattled drugmaker Valeant Pharmaceuticals International (VRX) and Rodelis Therapeutics are among companies that dramatically raised prices on some decades-old, off-patent drugs they acquired and controlled through monopoly business models, the report said.

"The skyrocketing prices of affect every American family, particularly our seniors," said Sen. Susan Collins, R-Maine, who chairs the committee. "We must work to stop the bad actors who are driving up the prices of drugs that they did nothing to develop ... just because, as one executive essentially said, 'because I can.'"

Sen. Claire McCaskill, D-Mo., the panel's ranking minority member, criticized what she termed the "predatory" hedge fund model of drug pricing. She called it "immoral for the patients and taxpayers who ultimately foot the bill—especially for generic drugs that can be made for pennies a dose."

The and Shkreli did not immediately respond to messages seeking comment on the report, which focused on the impact spiraling drug prices can have on ordinary Americans.

One was Isla Weston, a North Carolina infant who was diagnosed with a life-threatening parasitic infection called toxoplamosis in May 2015.

Doctors prescribed Daraprim, a drug that has been available since 1953 and is considered the standard treatment for the infection. But Shannon and Joshua Weston, the baby's parents, discovered that Turing Pharmaceuticals raised the per-tablet price of the medication by more than 5000%—from $13.50 to $750—shortly after acquiring the drug's rights from another company.

"I was hopeless and depressed at the thought of what would happen to my perfect little girl if I was not able to help her," Shannon Weston said during a March hearing held by the Senate committee. "I looked into any way I could think of to come up with the almost $360,000 necessary to treat my daughter for a year with a drug that she needed."

The baby ultimately received at least a year's supply of the drug for $200 a month from the University of North Carolina Medical Center's pharmacy, Weston testified.

Explore further: Senators urge action to block drastic drug price hikes

Related Stories

Senate panel investigates drug price hikes

November 4, 2015

A Senate committee tasked with protecting seniors is launching an investigation into prescription drug pricing, responding to public anxiety about companies hiking prices for once-inexpensive medicines.

Congress: drugmakers planned price hikes to boost profits

February 2, 2016

Two drugmakers have made a practice of buying and then dramatically hiking the prices of low-cost drugs given to patients with life-threatening conditions including heart disease, AIDS and cancer, according to excerpts from ...

Recommended for you

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

1 / 5 (1) Dec 27, 2016
Sadly government is the worse device for drug discovery and distribution when compared to free markets. The survival of drug companies is far, far, far more important than the survival of patients early in the drug discovery profile. Drug companies, makers of pharmaceuticals, must support robust drug discovery, the golden goose of medicine's improvement, and adding layers for public relations work to soothe US congressional ignoramuses is the real cost here. Drug companies must be free to set their own offerings, how much and at what price, and drug companies must heed the market place's demands, or pay with their very corporate existence. Governments cost society more, and do far less, and would do better to assist private laboratories than to fund their own government CDC and NIH-type labs so bloated, hopelessly obsolete, and politically astute that they are nearly worthless.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.